It is well past time to stop this negative BS concerning Replicel.
Collapse
X
-
-
Comment
-
Quoting David Hall from the Tobin Smith interview:
"clearly, if we demonstrate hairgrowth in excess of 20%, you're gonna attract alot of attention from biotech and big pharma"
3.2% is where they are at.Comment
-
subject.... predicate......
nobody is saying there isn't room for improvement... were just saying currently you're better off on rogaine... and probably will be for some time..... long enough a time that you probably shouldn't hope for much from replicel unless there is some DRASTIC, and i mean DRASTIC, changes over the next months/trial
and lastly, I'd like to pose what is probably the most important question for Replicel:
WHAT WENT WRONG? or, DO YOU HAVE A STRATEGY (and the data) TO DETERMINE WHAT WENT WRONG?
I mean to me, it sounds like they're just rolling dice. 1000x typical dosage? now they're going to do less? I mean what is going on? also, people keep saying maybe these hairs will eventually grow.... has replicel stated anywhere that they think this is a possibility? or is that forum speculation?-- it's bad news if the PR or the interview didn't mention this
also, has tracy answered any question yet posed? All i see is her replying with more questions-- all revolving around being "so dumb" "that dumb" "real dumb" etc.... at least follow it up with an explanation.Comment
-
Whilst I don't always agree with Tracey, she ain't no troll. I give her credit for ringing in during the live broadcast and at least she is trying to perform some sort of service to others in terms of advice.
Nothing wrong with cautious optimism either guys. Too many people were expecting the April results to realise their dreams. It's a small step in the right direction. - let's wait and see!Comment
-
And, of course, my original point was not that demonstrating safety was vastly, vastly more important than demonstrating efficacy, but that the nature of the trial, as in all phase I trials, was skewed very heavily towards testing safety and not efficacy. Sure, the efficacy results were not encouraging, but neither was the trial anything close to being a full-blown test of efficacy.Comment
-
Most people with ordinary reading comprahension skills can understand that the word "if" is a conditional and doesn't promise anything.
And, of course, my original point was not that demonstrating safety was vastly, vastly more important than demonstrating eficacy, but that the nature of the trial, as in all phase I trials, was skewed very heavily towards testing safety and not efficacy. Sure, the eficacy results were not encouraging, but neither was the trial anything close to being a full-blown test of eficacy.Comment
-
When the CEO appears on interviews claiming that they fully expect to exceed >20% growth, when a bunch of websites and analysts are paid to promote the product as a cure for hair loss, and then results are released which show absolutely no tangible growth, of course people aren't going to be positive about the results and Replicel.
Yeah, I'm sure companies are going to stop their research based on what's written on Bald Truth Talk.Comment
-
We may not think it - but what we say on these forums reaches further than we'd expect - we all know how small things on the internet can go viral worldwide in a matter of hours. What's saying we havent done the same with this entire burst of interest in the recent Replicel results?
These threads receive hundreds of thousands of views, there's a colossal community out there that is clearly interested in hair loss research, albeit most of them remaining in silence.Comment
-
Comment
-
Everyone but replicel is bugging out about efficacy and regrowth. Like i really dont think replicel would continue on to the next phase if they didnt think it's going to have twice as much regrowth with more time and fixing. Why the hell would replicel want to waste money and precious time if they think the efficacy is going to be 3 percent or what not. People need to stop freaking about this because replicel seems calm and pleased to stay on track and be the treatment for the future.Comment
-
Everyone but replicel is bugging out about efficacy and regrowth. Like i really dont think replicel would continue on to the next phase if they didnt think it's going to have twice as much regrowth with more time and fixing. Why the hell would replicel want to waste money and precious time if they think the efficacy is going to be 3 percent or what not. People need to stop freaking about this because replicel seems calm and pleased to stay on track and be the treatment for the future.Comment
-
This is a tiny little public company with funding problems and competition (ARI, Histogen, Follica, etc). Because of this, they had to design the trial to produce as much success as they could in a phase 1 safety trial to develop investor interest. This isn't some massive university cancer research department with government funds where they can just throw shit at the wall and hope it sticks. They needed results, and they definitely underwhelmed.
Over the past couple months, the company completed offerings worth a couple million dollars or so at $1.50/share (which at that time was well below market value). Now market value for shares is $1.27. They are going to have to sell more of their interest for less money now. Not to mention, whoever it was that bought in at $1.50 has to be pretty pissed off to be sitting underwater now and might not throw any more money at the company.Comment
-
No, efficacy wasn't more important than proving safety. But efficacy was a whole lot more important than many here are making it out to be.
This is a tiny little public company with funding problems and competition (ARI, Histogen, Follica, etc). Because of this, they had to design the trial to produce as much success as they could in a phase 1 safety trial to develop investor interest. This isn't some massive university cancer research department with government funds where they can just throw shit at the wall and hope it sticks. They needed results, and they definitely underwhelmed.
Over the past couple months, the company completed offerings worth a couple million dollars or so at $1.50/share (which at that time was well below market value). Now market value for shares is $1.27. They are going to have to sell more of their interest for less money now. Not to mention, whoever it was that bought in at $1.50 has to be pretty pissed off to be sitting underwater now and might not throw any more money at the company.Comment
Comment